Dr. Ryan P. Williams, MD
Child Neurology (Neurology with Special Qualifications in Child Neurology Physician)
850 Southampton Ave
Norfolk, VA 23510
Who else practices at this address →
Norfolk city is a federal dental shortage area. About shortage areas
At a glance
- Medical school
- Stanford University School of Medicine (2010)
- Years since graduation
- 16
- In the NPI registry since
- 2010
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2010Medical school: Stanford University School of Medicine
- 2010Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology with Special Qualifications in Child Neurology Physician primary
VA license 0101262602
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Childrens Specialty Group PLLC (85 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Payments from drug and device companies
In 2025, 7 companies reported 15 payments worth $2,469 in total to this clinician.
| Lundbeck LLC | $1,326 |
|---|---|
| Livanova USA, Inc. | $718 |
| UCB, Inc. | $173 |
| Axsome Therapeutics, Inc. | $93.54 |
| Neurelis, Inc. | $91.48 |
| Supernus Pharmaceuticals, Inc. | $41.51 |
| Aquestive Therapeutics, Inc. | $24.78 |
| Consulting Fee | $1,275 |
|---|---|
| Food and Beverage | $894 |
| Travel and Lodging | $300 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Lundbeck LLC Dec 11, 2025 | Consulting Fee VYEPTI · NEUROLOGY | $1,275 |
| Livanova USA, Inc. Mar 28, 2025 | Travel and Lodging VNS Therapy · Neurology · travel to Washington, DC · in-kind | $300 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 10 industry-funded studies in 2025, from 5 companies. The companies reported $51,230 in research payments for these studies, mostly to the institutions running them.
- A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine
H. Lundbeck A S · Recruiting · NCT04965675 - A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Children (6 to < 12 Years) and Adolescents (12 to < 18 Years) With Episodic Migraine (OA…
Amgen Inc. - Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
AbbVie Inc. · Recruiting · NCT05125302 - A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine
H. Lundbeck A S · Recruiting · NCT05164172 - A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatm…
Teva Pharmaceuticals USA, Inc. - A Study of Eptinezumab in Pediatric Participants With Episodic Migraine
H. Lundbeck A S · Recruiting · NCT05897320 - Phase 3 multicenter openlabel study to assess the longterm safety and tolerability of rimegepant for the acute treatment of migraine with or without aura in children and adolescents 6 to 18 years of age
Pfizer Inc. - Phase 3 multicenter randomized doubleblind group sequential placebocontrolled study to assess efficacy and safety of rimegepant for the treatment of migraine with or without aura in children and adolescents 6 to 18 …
Pfizer Inc. - A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Children (6 to < 12 Years) and Adolescents (12 to < 18 Years) With Chronic Migraine (OAS…
Amgen Inc. - A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pedia…
Teva Pharmaceuticals USA, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.